References

1. Axtelle T, Pribble J. (2001) IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res, 7 (4): 310-4. [PMID:11717588]

2. Axtelle T, Pribble J. (2003) An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody. J Endotoxin Res, 9 (6): 385-9. [PMID:14733726]

3. Gelevski D, Addy G, Rohrer M, Cohen C, Roderick A, Winter A, Carey J, Scalia J, Yerton M, Weber H et al.. (2023) Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol. Muscle Nerve, 67 (5): 354-362. [PMID:36533976]

4. Olszyna DP, Verbon A, Pribble JP, Turner T, Axtelle T, van Deventer SJ, van der Poll T. (2003) Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia. Eur Cytokine Netw, 14 (3): 158-62. [PMID:14656690]

5. Reinhart K, Glück T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, Opal S, Moldawer LL, Axtelle T, Turner T et al.. (2004) CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med, 32 (5): 1100-8. [PMID:15190957]

6. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle T, Hoek FJ, van Deventer SJ et al.. (2001) IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol, 166 (5): 3599-605. [PMID:11207321]

7. Verbon A, Meijers JC, Spek CA, Hack CE, Pribble JP, Turner T, Dekkers PE, Axtelle T, Levi M, van Deventer SJ et al.. (2003) Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis, 187 (1): 55-61. [PMID:12508146]